公开(公告)号：WO2010011824A1

公开(公告)日：2010-01-28

申请号：PCT/US2009/051510

申请日：2009-07-23

Applicant: CONCERT PHARMACEUTICALS, INC. ,  MASSE, Craig, E.

Inventor： MASSE, Craig, E.

IPC: A61K31/407

CPC classification number: C07D487/04

Abstract: This invention relates to novel xanthine compounds, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an adenosine Al receptor (AAlR) antagonist.

Abstract translation: 本发明涉及新颖的黄嘌呤化合物，其衍生物，其药学上可接受的盐。 本发明还提供了包含本发明化合物的组合物和这些组合物在治疗通过施用腺苷A1受体（AA1R）拮抗剂有益治疗的疾病和病症的方法中的用途。

公开(公告)号：WO2009067225A3

公开(公告)日：2009-07-09

申请号：PCT/US2008012949

申请日：2008-11-20

Applicant: CONCERT PHARMACEUTICALS INC ,  MASSE CRAIG E

Inventor： MASSE CRAIG E

IPC: A61K38/06 ,  A61P31/14 ,  C07K5/08

CPC classification number: A61K38/06 ,  C07K5/06034

Abstract: This invention relates to novel compounds that are peptides derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel peptides that are derivatives of boceprevir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an HCV NS3/NS4A protease inhibitor, such as boceprevir.

Abstract translation: 本发明涉及新型化合物，其为肽衍生物及其药学上可接受的盐。 更具体地说，本发明涉及作为boceprevir衍生物的新型肽。 本发明还提供了包含一种或多种本发明化合物和载体的组合物以及所公开的化合物和组合物在治疗疾病和病症的方法中的用途，所述疾病和病症通过施用HCV NS3 / NS4A蛋白酶抑制剂如波西普韦而受益地治疗。

公开(公告)号：WO2009023233A1

公开(公告)日：2009-02-19

申请号：PCT/US2008/009704

申请日：2008-08-14

Applicant: CONCERT PHARMACEUTICALS, INC. ,  MASSE, Craig, E.

Inventor： MASSE, Craig, E.

IPC: C07D413/14 ,  A61K31/5377 ,  A61P7/02

CPC classification number: C07D413/14

Abstract: This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use of the disclosed compounds and compositions in methods of treating diseases and condition that are beneficially treated by administering a selective inhibitor of factor Xa, such as rivaroxaban.

Abstract translation: 本发明涉及取代的恶唑烷酮衍生物的新化合物及其药学上可接受的盐。 更具体地，本发明涉及作为利伐沙班的衍生物的新的恶唑烷酮化合物。 本发明还提供了包含一种或多种本发明化合物和载体的无热原组合物，以及所公开的化合物和组合物在治疗通过施用选择性因子Xa抑制剂有益治疗的疾病和病症的方法中的用途， 作为利伐沙班。